Immunotherapy in Advanced Cutaneous Melanoma: From the Optimal Treatment Duration to the Impact on Survival in Case of Early Discontinuation Due to Immune-Related Adverse Events

Immune checkpoint inhibitors (ICIs) have improved the prognosis of patients with cutaneous melanoma. Immunotherapy (IT) is generally well tolerated, but an increasing area of investigation concerns the optimal treatment duration of anti-programmed cell death-1 (anti-PD1) regimens to limit the immune...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Giacomo Triggiano, Gaetano Pezzicoli, Marco Tucci
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2025-04-01
Schriftenreihe:	Biomolecules
Schlagworte:	cutaneous melanoma immune checkpoint inhibitors immune-related adverse events anti-PD1 combo-immunotherapy treatment discontinuation
Online-Zugang:	https://www.mdpi.com/2218-273X/15/5/651
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!